Literature DB >> 10325756

Final height in girls with Turner's syndrome treated with once or twice daily growth hormone injections. Dutch Advisory Group on Growth Hormone.

T C Sas1, S M de Muinck Keizer-Schrama, T Stijnen, A van Teunenbroek, A C Hokken-Koelega, J J Waelkens, G G Massa, T Vulsma, W J Gerver, H M Reeser, H E Delemarre-van de Waal, M Jansen, S L Drop.   

Abstract

OBJECTIVES: To study final height in girls with Turner's syndrome treated with once or twice daily injections of growth hormone (GH) in combination with low dose ethinyl oestradiol.
DESIGN: Until final height was reached, the effect of fractionated subcutaneous injections given twice daily was compared with once daily injections of a total GH dose of 6 IU/m2/day. Twice daily injections were given as one third in the morning and two thirds at bedtime. All girls concurrently received low dose oestradiol (0.05 microgram ethinyl oestradiol/kg/day, increased to 0.10 microgram/kg/day after 2.25 years). PATIENTS: Nineteen girls with Turner's syndrome aged > or = 11 years (mean (SD) 13.6 (1.7) years). MEASUREMENTS: To determine final height gain, we assessed the difference between the attained final height and the final height predictions at the start of treatment. These final height predictions were calculated using the Bayley-Pinneau (BP) prediction method, the modified projected adult height (mPAH), the modified index of potential height (mIPHRUS), and the Turner's specific prediction method (PTSRUS).
RESULTS: The gain in final height (mean (SD)) was not significantly different between the once daily and the twice daily regimens (7.6 (2.3) v 5.1 (3.2) cm). All girls exceeded their adult height prediction (range, 1.6-12.3 cm). Thirteen of the 19 girls had a final height gain > 5.0 cm. Mean (SD) attained final height was 155.5 (5.4) cm. A "younger bone age" at baseline and a higher increase in height standard deviation score for chronological age (Dutch-Swedish-Danish references) in the first year of GH treatment predicted a higher final height gain after GH treatment.
CONCLUSIONS: Division of the total daily GH dose (6 IU/m2/day) into two thirds in the evening and one third in the morning is not advantageous over the once daily GH regimen with respect to final height gain. Treatment with a GH dose of 6 IU/m2/day in combination with low dose oestrogens can result in a significant increase in adult height in girls with Turner's syndrome, even if they start GH treatment at a relatively late age.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10325756      PMCID: PMC1717808          DOI: 10.1136/adc.80.1.36

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  29 in total

1.  Does growth-hormone supplementation affect adult height in Turner's syndrome?

Authors:  S P Taback; R Collu; C L Deal; H J Guyda; S Salisbury; H J Dean; G Van Vliet
Journal:  Lancet       Date:  1996-07-06       Impact factor: 79.321

2.  Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards.

Authors:  N BAYLEY; S R PINNEAU
Journal:  J Pediatr       Date:  1952-04       Impact factor: 4.406

3.  Growth hormone secretion in pubertal age patients with Turner's syndrome.

Authors:  R Lanes; S Brito; M Suniaga; G Moncada; M Borges
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

4.  Turner syndrome: spontaneous growth in 150 cases and review of the literature.

Authors:  M B Ranke; H Pflüger; W Rosendahl; P Stubbe; H Enders; J R Bierich; F Majewski
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

5.  A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency.

Authors:  W F Blum; M B Ranke; K Kietzmann; E Gauggel; H J Zeisel; J R Bierich
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

6.  Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome.

Authors:  R G Rosenfeld; J Frane; K M Attie; J A Brasel; S Burstein; J F Cara; S Chernausek; R W Gotlin; J Kuntze; B M Lippe
Journal:  J Pediatr       Date:  1992-07       Impact factor: 4.406

7.  Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height.

Authors:  G Haeusler; K Schmitt; P Blümel; E Plöchl; T Waldhör; H Frisch
Journal:  Acta Paediatr       Date:  1996-12       Impact factor: 2.299

8.  Final height after long-term growth hormone treatment in Turner syndrome. European Study Group.

Authors:  J Van den Broeck; G G Massa; A Attanasio; A Matranga; J L Chaussain; D A Price; D Aarskog; J M Wit
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

9.  Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood.

Authors:  L M Carlsson; A M Rowland; R G Clark; N Gesundheit; W L Wong
Journal:  J Clin Endocrinol Metab       Date:  1991-12       Impact factor: 5.958

10.  Analyses of 24-hour growth hormone profiles in children: relation to growth.

Authors:  K Albertsson-Wikland; S Rosberg
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

View more
  5 in total

Review 1.  Long-term results of growth hormone therapy in Turner syndrome.

Authors:  J H Bramswig
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

Review 2.  Justified and unjustified use of growth hormone.

Authors:  A J van der Lely
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

Review 3.  Value of growth hormone treatment in Turner's syndrome.

Authors:  P Saenger
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

Review 4.  Ovarian function in girls and women with GALT-deficiency galactosemia.

Authors:  Judith L Fridovich-Keil; Cynthia S Gubbels; Jessica B Spencer; Rebecca D Sanders; Jolande A Land; Estela Rubio-Gozalbo
Journal:  J Inherit Metab Dis       Date:  2010-10-27       Impact factor: 4.982

5.  Adult height prediction by bone age determination in children with isolated growth hormone deficiency.

Authors:  Thomas Reinehr; Martin Carlsson; Dionisios Chrysis; Cecilia Camacho-Hübner
Journal:  Endocr Connect       Date:  2020-05       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.